BIOTHERAPEUTICS DEVELOPABILITY
AND RISK MITIGATION

WORKSHOP ORGANIZERS

Workshop n°1 - Part I

Tuesday, 22 September 2026

11h10

Best Practices in Host Cell Impurity Analytics - Using Advanced Technologies and Methods to Monitor and Control Host Cell Proteins

- Plenary

Chairman

Workshop Overview

Host cell protein (HCP) impurities are the main process-related impurities in biological drugs and can pose a risk to patients and affect drug efficacy and stability. As a critical quality attribute, HCP levels must be carefully monitored and controlled to ensure product safety and efficacy.

 

HCP analytics have come a long way over the last 25 years.  We have gone from a “black box” type approach that produced numbers that were semiquantitative at best to groundbreaking Mass Spectrometry techniques that can identify every host cell protein in a Drug Substance sample. HCP ELISA remains the workhorse for HCP analytics due to its utility, simplicity, robustness, and cost-effective nature. But we now have the tools to know exactly which HCP the assay can detect and which ones it will miss.

 

We will discuss how adoption of advanced technologies and methods for HCP analytics ensure that an HCP ELISA, whether it is a generic or a process-specific assay, is appropriate for use and allows data driven risk assessment to ensure drug product integrity and safety. Several case studies focusing on HCP antibody coverage assessment utilizing 2D PAGE- and MS-based methods will be presented. Additionally, data on LC-MS based HCP relative and absolute quantification will be presented.

Presenter

John LOCKLEAR

Associate Director - Assay Development and Technical Support

Cygnus Technologies

Workshop n°1 - Part II

Wednesday, 23 September 2026

11h10

Analytics for Other Process-related Impurities in Biologics: Protein A, Protein L, Host Cell DNA

- Plenary

Chairman

Workshop Overview

An overview of other host cell and process-related impurities, such as Protein A and Protein L Ligand Leachates, Host Cell DNA and requirements for impurity testing.  Data and case studies utilizing Cygnus Technologies novel solutions for the reproducible detection and quantification of these impurities will be presented.

Presenter

John LOCKLEAR

Associate Director - Assay Development and Technical Support

Cygnus Technologies

Workshop n°2

Tuesday, 22 September 2026

11h10

Accelerated Regulatory Pathways to Saudi Arabia: New SFDA Programs by Development Stage

- Plenary

Chairman

Summary

Most companies file in Saudi Arabia only after FDA or EMA approval. In 2026, that sequence became costly. The SFDA now operates a set of designations and accelerator programs; several of them are for investigational medicines. This workshop maps each program to the development stage where it applies. Participants leave with a clear view of their options when approaching Saudi Arabia. It is the country with the highest rare disease prevalence in the Middle East and Africa, where around 8% of births are affected by a genetic condition.

Presenter

Mohammed JOBRAN

Regulatory Affairs Consultant & Founder

PharmaKnowl Consulting, KSA

Workshop n°3

Tuesday, 22 September 2026

11h10

Optimising Biologic Drug Products: Connecting Formulation Science, Process Development and Advanced Analytics

- Plenary

Chairman

Summary

The development of robust biologic drug products requires analytical strategies that provide insight from molecular structure to particle formation. In this workshop, Jean-François Boé, PhD (Senior Director, Drug Product Development, Catalent) and Waters experts will demonstrate how complementary analytical technologies, including liquid chromatography (LC), mass spectrometry (MS), multi-angle and dynamic light scattering (MALS and DLS), and Aura™ backgrounded membrane imaging, can be applied throughout formulation and process development.

Using real-world examples, attendees will learn how these orthogonal techniques can be used to characterise molecular variants, monitor aggregation and particle formation, assess formulation stability, and evaluate the impact of process changes on product quality. Join us to discover how integrated analytical workflows can accelerate development, strengthen process understanding, and support the creation of stable, manufacturable biologic drug products.

Speakers

Ben WILKES

Principal Biologics Market Development Manager

Waters Corporation, UK

Jean-François BOE

Senior Director, Drug Product Development

Catalent Biologics

Nicolas MIGNARD

Principal System Sales Account Manager, Biologics Business

Waters Corporation, France

Workshop n°4

Tuesday, 22 September 2026 and Wednesday, 23 September 2026

General title

11h10

Collaborative 3D Serious Game: Investigate three real deviation cases using data-driven analysis

- Plenary

Workshop Overview

Join Immerscio.bio for a live demonstration of our digital training approach to bioproduction upskilling. In this workshop, you will collectively participate in one of our digital 3D serious games dedicated to data across the bioproduct lifecycle. Using your smartphones, you will investigate three real-life deviations encountered from development to manufacturing, working from available data to identify their root causes.
 
Join us to strengthen your understanding of how data supports decision-making in bioproduction, through a practical and collaborative scenario used in actual trainings.

Presenters

Cynthia HITTI

Digital Learning Sales Specialist

Immerscio.bio, France

Marc REIS

Customer Digital Solutions Specialist

Immerscio.bio, France

Farah DRISSI

Digital Learning Sales Specialist

Immerscio.bio, France

Workshop n°5

Tuesday, 22 September 2026

11h10

Decontamination in Bioproduction: Can Performance, Agility and Rapid Qualification Be Combined?

- Plenary

Chairman

Abstract

Bioproduction is becoming increasingly flexible and complex. Decontamination strategies must evolve accordingly: how can decontamination be made more flexible and easier to implement, while strengthening the level of scientific evidence?

Speaker

Charlotte GOURRAUD

Scientific and Quality Director

Devea Environnement, France

Workshop Organizer

About us

PharmaKnowl is a Saudi-based regulatory consulting firm licensed by SFDA, helping global pharmaceutical, biotech, and medical device companies navigate the Saudi Arabian market. We provide end-to-end regulatory affairs, clinical trial support, pharmacovigilance, and quality management services fully aligned with SFDA and GCC regulations and delivered by a local expert team based in Riyadh.
 
Founded in 2014, PharmaKnowl was established to address a critical gap in Saudi Arabia’s regulatory landscape. We offer international life sciences companies a trusted, locally embedded partner for SFDA registration, compliance, and market access.
 
From our origins as a regulatory advisory firm, we’ve grown into a comprehensive service provider supporting the full product lifecycle; from initial SFDA submissions through post-market surveillance. Our team combines deep local regulatory expertise with global industry understanding, bridging the expectations of multinational companies and the evolving standards of Saudi Arabia’s healthcare regulatory environment.
 

SPONSOR Bronze

About us

Hamilton Company specializes in the development, manufacturing and customization of precision measurement devices, automated liquid handling workstations, and sample management systems. Hamilton’s processes are optimized for quality and flexibility. Whether it’s a custom needle with a quick delivery time frame, a special length pH sensor, or a comprehensive solution to fully automate your assay workflow, Hamilton products will always meet your needs.
Hamilton headquarters are in Reno, Nevada; Franklin, Massachusetts; Timișoara, Romania; Bonaduz, Switzerland; and subsidiary offices throughout the world.

 

www.hamiltoncompany.com

SPONSOR Silver

About us

Immerscio.bio, powered by Campus Biotech Digital, is a training organization offering digital programs dedicated to biopharmaceutical production. Our offering includes 69 immersive training modules using 3D, virtual reality, and serious games, covering every stage of the value chain: industrialization, manufacturing, quality control and supply chain. Designed with academic and industrial partners, our programs combine cGMP compliance, innovative pedagogy, and immersive learning to strengthen skills and accelerate employability, while meeting the strategic challenges of biopharmaceutical production.


immerscio.bio | contact@immerscio.com

SPONSOR Silver

About us

With a storage capacity of more than 20 million biological samples, the BioKryo network operates in three European countries, with four dedicated sites. Each site offers a complete range of cryogenic services, including storage temperatures from -196°C to +20°C with all associated services including cryogenic sample transport. This service is destined for research teams in the human and veterinary health sector, pharmaceutical or cosmetic industries, wishing to secure their samples, duplicate their collections or free up space in their premises. Within the BioKryo network, all processes and quality systems are harmonized to meet the highest quality and safety standards for diagnostic, research and therapeutic purposes, wherever a sample is stored. Sample monitoring and traceability is ensured 24/7/365 in a doubled and automatic control by teams of technicians and biologists. All sites comply with Good Manufacturing Practices (GMP) for the reception, storage and provision of biological samples.


https://biokryo.airliquide.com/fr

https://biokryo.airliquide.com/fr/contact

Fabien Compeau

Design and development of chemically defined media supplemented with vegetable protein hydrolysates to enhance CHO cell growth and monoclonal antibody production

Abstract

In the realm of biopharmaceutical production, Chinese Hamster Ovary (CHO) cells have emerged as the main expression system for recombinant therapeutic proteins (RTPs), despite the availability of several alternative cell lines. CHO cells are among the most widely used worldwide for their unique advantages, e.g, the variety of post-translational modifications that closely mimic those found on human cells (Stach et al. 2019); their high degree of biosafety due to their low risk of propagation of human viruses infection (Lalonde and Durocher, 2017); their adaptability from adherent to suspension cell culture in serum-free media (Davami et al. 2014). Thanks to these combined attributes that solidified the position of CHO cells, they have become the gold-standard of the bioindustry and are responsible for the production of approximately 70% of all marketed RTPs (Pereira et al., 2018; Stolfa et al., 2018; Dziomba et al. 2023).

 

Fetal bovine serum (FBS) is commonly used as a supplement to basal media for in vitro cell cultures (including mammalian, animal, insect, and bacterial cells). Many studies have revealed its rich composition, containing essential macro- and micronutrients such as growth factors, adherent factors, amino acids, hormones, and vitamins (Michael Butler et al. 2020), which are crucial for proper cell function. In addition to the ethical issue, increasing demand, high cost, significant contamination risks (bacterial and viral), and batch-to-batch variability of FBS prompt us to seek alternatives. To reduce or eliminate FBS use, we have decided to implement culture media with various plant protein hydrolysates. Although serum-free media have been available for several decades, and their widespread adoption has increased, despite the fact that their compositions are undefined for users. Our goal is to make these serum-free media more accessible considering that serum-free media cost about 1.5 to 3 times more than serum-containing media.

 

Several publications highlighted the effects of vegetable proteins hydrolysate (peptones) as supplements in basal media, i.e : the enhancing of the cell growth and productivity of recombinant proteins (Burteau et al. 2003; Michael J. Betenbaugh et al. 2020). Some publications have shown an enhancing of the volumetric productivity more than 100%, and a 40% increase in cell number (Davami et al. 2014; Davami et al. 2015). Then, the composition of these plant hydrolysates varies according to the plant source and the production process. Thanks to their vegetable origins there are neither ethical issues, nor health standards.

 

In the present study, the effect of different peptone concentrations on the CHO-K1 cell line under various culture conditions (adherent/suspension) in a basal medium with a 10-fold reduction of FBS have been evaluated. Supplementation with wheat peptones at defined concentrations increased the viable cell density of CHO-K1 in adherent conditions by 190 – 265%.

 

Additionally, the suspension culture exhibited different results compared to the adherent conditions. In suspension cell culture, only three peptones – wheat, soy, and pea – enhanced viable cell density compared to the medium without hydrolysates. Actually, the only peptone supplementation is not enough to be completely serum-free, but that can reduce the FBS consumption.

Biography

Fabien Compeau is a researcher at both Organotechnie and Université Sorbonne Paris Nord, within the Tissue Engineering Research Unit. With a solid foundation in molecular and cellular biology. His current work centers on developing serum-free media. He completed three years of study at CY Cergy Paris Université and two years at Université Paris Cité. His internships provided valuable experience at the Institut de Recherche Criminelle de la Gendarmerie Nationale, the Institut Jacques Monod, and the Institut Pasteur, his research
focused on cell signaling, dynamics, and differentiation.

Igor Chourpa

Molecular optical spectroscopy as a PAT tool in USP bioprocessing

Abstract

Process analytical technology (PAT) aims at real-time, sampling-free monitoring of bioprocesses, for instance at the upstream stage (USP), when suspensions of CHO (chinese hamster ovary) cells grow in bioreactors and produce monoclonal antibodies (mAbs). The advantages of in-line PAT over the off-line approaches are numerous, from scientific, economic and ecological points of view. Using light as a non-invasive PAT tool is one of the promising ideas that give rise to various technological solutions. Nevertheless, the implementation of novel PAT approaches is limited and still requires further progress in analytical instrumentation and its integration in the whole process.
In this talk, we plan to present a short overview of advances in implementation of molecular optical spectroscopy as a PAT tool in upstream processing of therapeutic antibodies we obtained in the framework of our interdisciplinary research project CLIMB’IN. The project uses analytical spectroscopy based on light absorption and/or multi-angle scattering, both elastic (Rayleigh) and inelastic (Raman) for quantitative monitoring of multiple critical process parameters (CPPs). The advances reached by the CLIMB’IN consortium involve instrumental design and experimental protocols, with a particular focus made on machine learning algorithms. Brought together, these advances allow to improve the relevance and the robustness of the corresponding PAT approaches required for their industrial implementation.

Anne-Sophie GARY

Innovative tools to monitor biological variability of bioprocesses

Abstract

Today, virus-based products like oncolytic viruses and gene therapies are part of the most promising biotherapies. The development of biomanufacturing processes for viral products is not a straight road. It is generally associated with process complexity and biological variability. In depth expression system characterization by adding biological data to standard chemical data will help to understand bioprocesses. With a close collaboration between Naobios and Gensensor, case study from Vero cell substrate-based process will illustrate how transcriptomic data may help to understand and monitor biological variability linked to bioprocesses.

Biography

Anne-Sophie has a PhD in cell biology and is engineer in biotechnology. After working on cell stress and death pathways, Anne-Sophie specialized in the development of advanced therapy medicinal product. Now Principal Scientist at GenSensor, she is in charge of identifying biomarker panels on different expression systems and leads, with her team, the company’s internal research projects and scientific collaborations.